Loading…
← CockpitCompetitor Analysis › CYTK Cytokinetics, IncorporatedOpen in the cockpit ↗

Cytokinetics, IncorporatedCYTKCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Biotech developing muscle-targeted drugs, including aficamten for hypertrophic cardiomyopathy, awaiting its first approval.

Momentum laggard 14
Mkt cap
$7.15B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$121M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 7.1%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$51.32
1D-0.6%
1W-12.3%
1M-19.8%
3M-33.5%
6M-34.9%
YTD-19.2%
1Y-23.4%
ATR %5.1%
Beta1.03
52w lowhigh41.9% off high

What Cytokinetics does

Biotech developing muscle-targeted drugs, including aficamten for hypertrophic cardiomyopathy, awaiting its first approval.

Has lived on partner payments, royalty-financing deals and share sales rather than product sales, with trial and launch costs funded from outside. The business is built around one drug class, cardiac myosin inhibitors, which act directly on how heart muscle contracts.

Products and services

  • Aficamten (hypertrophic cardiomyopathy, pipeline)
  • Muscle-biology drug-discovery platform

Customers

  • Cardiologists
  • Health systems
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • Cardiac and skeletal muscle disease

What could go right

  • First commercial approval of aficamten
  • Large underdiagnosed hypertrophic cardiomyopathy population

What could go wrong

  • Pre-revenue/pre-approval clinical risk
  • Competing already-approved drug (Camzyos) from Bristol Myers

Moat: narrow (IP / patents, process know-how). Deep expertise in cardiac muscle mechanics from a long-running R&D heritage tied to Amgen.

Headquarters: South San Francisco, California, United States · Founded: 1997 · Employees: 673

Named competitors

Cytokinetics at a glance

Size Cytokinetics (CYTK) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $7.15B, the 947th largest of 3,085 United States companies the cockpit tracks. Shares closed at $51.32 on 18 Nov 2026.

Performance Over six months the shares fell 34.9%, against +5.9% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth Revenue grew 29.9% over the last twelve months (peer median +8.9%); the operating margin is -625.1% (peer median 15.1%).

Valuation It trades at 64.3× enterprise value to sales against a peer median of 4.8× (most expensive of 19).

Credit Cytokinetics has 2 bonds outstanding ($891M).

Short interest Short interest is 12.9% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 107CYTK 66
Six months, rebased to 100: Cytokinetics against the median of its 20 peers (local-currency closes).

Cytokinetics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$113M$88.0M$18.5M$7.53M$94.6M
Revenue growth—+377%+145%-92%—
Gross profit$89.4M$77.9M$8.94M-$4.36M$86.2M
EBITDA-$695M-$602M-$527M-$484M-$316M
Net income-$778M-$785M-$590M-$526M-$389M
Free cash flow-$589M-$535M-$400M-$416M-$311M
Capital expenditure$16.6M$24.8M$3.91M$1.42M$11.3M
Total debt$1.27B$1.28B$789M$756M$749M

Quarterly statements and history in the cockpit →

Cytokinetics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%IBRX6821BANB99264528CORTKNSAGRF600196AMRX000963ALKEMORKAALKS0126Z0BLTEGLENMARKCYTK6-month return →1-month return →
Up and to the right = strong over both horizons. Cytokinetics is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×20×40×60×IBRX6821BANB99264528CORTKNSAGRFALKSGLENMARKCYTKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Cytokinetics is the large dot.

Cytokinetics competitors and peer comparison

Head to head with its named competitors (CYTK vs BMY vs NOVN.SW vs EWTX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Cytokinetics CYTK$7.15B-35%+30%-625%64.3×n/a
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%
Novartis NOVN.SW$285B+11%-4%30%6.2×1.6%
Edgewise Therapeutics EWTX$4.53B+26%n/an/an/an/a

How Cytokinetics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cytokinetics against its 20 peers (data as of 18 Nov 2026)
MeasureCYTKPeer medianRank in peer set
1-month return-19.8%+2.2%5th lowest of 21
6-month return-34.9%+5.9%2nd lowest of 20
Distance from 52-week high-41.9%-14.9%5th lowest of 21
Revenue growth (TTM)+29.9%+8.9%5th highest of 18
Operating margin-625.1%15.1%lowest of 19
EV / Sales64.3×4.8×most expensive of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%64.3×n/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%44.3×n/an/a
Asymchem Laboratories (Tianjin) 6821.HKHong Kong$7.10B+17%+24%17%5.8×n/an/a
Bachem BANB.SWSwitzerland$7.06B0%+5%19%8.6×n/an/a
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%12.9×n/an/a
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%2.1×-6.8%+10.8%
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%7.3×23.9%+16.6%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%7.3×10.4%+45.5%
Grifols GRF.MCSpain$7.48B+19%+1%16%2.4×7.1%+7.1%
Shanghai Fosun Pharmaceutical (Group) 600196.SSChina$7.57B-14%+8%6%2.1×2.9%+6.6%
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%3.4×17.2%+8.7%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%1.1×-3.9%+5.3%
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%4.1×25.0%+10.7%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%1.9×-6.2%+18.4%
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%3.5×-11.9%+4.2%
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a
Alkermes Public ALKSUnited States$7.87B+27%+15%5%5.0×32.5%+7.3%
Samsung Epis 0126Z0.KSSouth Korea$6.49B-31%n/a12%5.9×n/an/a
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%7.4×7.3%+12.6%
Belite Bio, Inc. ADR BLTEUnited States$6.41B+9%n/an/an/an/an/a
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%4.7×27.3%+9.4%

Cytokinetics bonds and credit

Cytokinetics has 2 bonds outstanding with $891M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Cytokinetics's main competitors?
Named competitors: Bristol Myers Squibb (Camzyos) (BMY), Novartis (NOVN.SW), Edgewise Therapeutics (EWTX). The cockpit's measured peer set (industry) also includes ImmunityBio (IBRX), Asymchem Laboratories (Tianjin) (6821.HK), Bachem (BANB.SW), Akeso (9926.HK), ONO Pharmaceutical (4528.T), Corcept Therapeutics (CORT).
Is Cytokinetics expensive compared with its peers?
On ev / sales it trades at 64.3× against a peer median of 4.8×, most expensive of 19 in its peer set.
How has Cytokinetics stock performed?
Over six months to 18 Nov 2026 the shares returned -34.9% against +5.9% for the median peer; over one year -23.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.